Health Care Dividend Stocks: MRK, MDT, UNH Analysis

On March 17, 2026, Benzinga published an analysis highlighting three healthcare stocks with dividend yields exceeding 3%—Merck & Co (MRK), Medtronic PLC (MDT), and UnitedHealth Group (UNH) [1]. This report integrates market data, analyst sentiment, and company-specific developments to provide a comprehensive view of these dividend opportunities in the healthcare sector.

The healthcare sector demonstrated modest strength on March 17, 2026, posting a +0.38% gain and ranking fourth among 11 sectors [0]. This performance occurred amid a mixed market day where consumer cyclical stocks led with +0.75% and consumer defensive stocks lagged at -1.01% [0]. The positive healthcare sector movement indicates sustained investor interest in dividend-paying healthcare names during periods of market uncertainty.

trades at $115.42 with a 2.95% dividend yield and 15.85x P/E ratio, representing the most attractive valuation among the three [0]. Wells Fargo raised the price target to $150, highlighting Sac-TMT’s potential as a best-in-class TROP2 antibody-drug conjugate that could replace chemotherapy in several cancer indications [1][2]. However, Keytruda faces patent expiration in 2028, and Gardasil sales declined 39% in 2025 due to weakened Chinese demand [2].

shows the highest dividend yield at 3.22% with a current price of $88.24 and 24.65x P/E [0]. The stock has demonstrated strength with +1.26% daily performance and trades near the lower end of its 52-week range ($79.55-$106.33) [0]. Needham maintains a Buy rating with $120 price target, while JP Morgan holds Neutral with a reduced $100 target [1]. The company is seeking to overturn a $382 million antitrust loss to rival Applied Medical [4].

trades at $285.49 with a 3.10% dividend yield and 21.58x P/E [0]. The stock has declined approximately 53% from its 52-week high of $606.36, presenting a potentially attractive entry point [0]. Despite revenue reaching $447.6 billion in 2025 (up 12% YoY), GAAP EPS fell to $13.23 with net margins of just 2.7% due to Medicare reimbursement cuts, IRA impacts on Part D, and elevated medical costs [9]. The 2026 guidance targets adjusted EPS above $17.75 with margins recovering to approximately 5.5% [9].

: All three stocks trade significantly below their analyst price targets—MRK trades 23% below its $150 target, MDT trades 26% below its $120 target, and UNH trades 23% below its $350 target [1][0]. This suggests substantial upside potential if the companies execute on their respective strategies.

: The healthcare sector’s +0.38% gain during a mixed market day demonstrates the defensive nature of healthcare dividend stocks. During market turbulence, investors historically gravitate toward companies with high free cash flows and sustainable dividend payouts—characteristics shared by all three analyzed stocks [1].

: Each stock faces distinct challenges—MRK must navigate Keytruda’s 2028 patent expiration while developing pipeline replacements [3]; MDT contends with a $382 million antitrust judgment that could materially impact finances if upheld [4]; UNH must execute on margin recovery while facing ongoing Medicare reimbursement pressure [9]. Conversely, each has positive catalysts—MRK’s Sac-TMT pipeline [2], MDT’s Scientia Vascular acquisition [1], and UNH’s AI-driven operational efficiency initiatives [8].

: All three companies maintain strong operating cash flows—UNH generated $19.7 billion in operating cash flow [9]—providing fundamental support for dividend sustainability. MDT’s status as a Dividend Aristocrat adds further credibility to its payout [5].

1. Pipeline/Patent Risk (MRK)
   : Keytruda represents a substantial portion of Merck’s revenue, and the 2028 loss-of-exclusivity creates meaningful uncertainty [3]. The company projects $70 billion in potential commercial opportunities by the mid-2030s from new products, but execution risk remains.

2. Legal Risk (MDT)
   : The $382 million antitrust judgment, if upheld, could materially impact Medtronic’s financials [4]. The company argues the verdict is an “extreme outlier” and is pursuing an appeal [4].

3. Margin Pressure (UNH)
   : Medical cost inflation and Medicare reimbursement cuts continue to pressure profitability [9]. The company’s ability to achieve 2026 margin recovery targets depends on successful repricing initiatives.

4. Regulatory Risk (All Stocks)
   : Healthcare policy changes can significantly impact reimbursement rates and drug pricing across the sector [9].

1. Attractive Valuations
   : All three stocks trade below analyst price targets with P/E ratios ranging from 15.85x to 24.65x, representing potential entry points for income-focused investors [0].

2. Defensive Sector Positioning
   : Healthcare spending remains resilient regardless of economic conditions, providing stability during market volatility [1].

3. UNH Recovery Potential
   : The stock’s 53% decline from its 52-week high presents a potentially attractive entry point if the 2026 margin recovery materializes as guidance suggests [0][9].

4. MDT Value Opportunity
   : Trading near the lower end of its 52-week range with the highest dividend yield (3.22%) among the three, MDT represents a potential value opportunity for income investors [0][5].

This analysis synthesizes findings from Benzinga’s coverage of healthcare dividend stocks and supporting analyst reports [1]. The three analyzed stocks—MRK, MDT, and UNH—all offer dividend yields exceeding 3% and trade below their analyst price targets, representing potential upside for income-focused investors.

• MRK: $115.42, 2.95% yield, 15.85x P/E, $285B market cap [0]
• MDT: $88.24, 3.22% yield, 24.65x P/E, $113B market cap [0]
• UNH: $285.49, 3.10% yield, 21.58x P/E, $259B market cap [0]

• MRK: Overweight ratings from Wells Fargo ($150 target) and RBC ($142 target) [1][2]
• MDT: Mixed—Buy from Needham ($120), Neutral from JPM ($100) [1]
• UNH: Outperform from Mizuho ($350), Buy from Truist ($370), but with reduced targets [1]

Investors should weigh company-specific challenges—Keytruda LOE for MRK, antitrust liability for MDT, and Medicare reimbursement pressure for UNH—against the stability of 3%+ yields in a historically defensive sector. The healthcare sector’s +0.38% performance on March 17 suggests continued market interest in these dividend opportunities [0].